The effect of oral miltefosin on treatment resistant cutaneous leishmaniasis

Effect of oral miltefosin on treatment of chronic anthropological cutaneous leishmaniasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200302046673N1

Enrollment

Registered

2020-05-10

Start date

2019-04-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis Antroponotic. Cutaneous Leishmaniasis

Interventions

Intervention Group: Miltefosin made in PROFONDA Co.in India 50 mg. 2.5mg/kg/day for 28 days.

Eligibility

Sex/Gender

All

Age

2 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals with antroponotic leishmaniasis over two year who have not received remission despite two courses of systemic glucontime or one cours of systemic glugantime plus one course of intraleasional injection

Exclusion criteria

Exclusion criteria: Children Under Two Year Pregnancy and Lactation Renal Disorer Liver Disorder Heart Disease Cytopenia

Design outcomes

Primary

Measure	Time frame
Endoration Rate of Leasion. Timepoint: Study days 0,14,28,90,180,360. Method of measurement: Ruler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoume Tayebi

Mashhad University of Medical Sciences

Tayyebims961@mums.ac.ir+98 51 3867 5473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026